Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial
机构:[1]Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China[2]College of Economics and Management, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China[3]Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province 510060, China中山大学肿瘤防治中心[4]The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510405, China广东省中医院[5]The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510120, China广东省中医院
Background: Because of medical advances, metastatic breast cancer (MBC) is now viewed as a chronic disease, rather than an imminent death sentence. Helping women live with this disease requires more than a medical approach to symptoms. Thus, a mentor-based and supportive-expressive program 'Be Resilient to Breast Cancer' (BRBC) was designed to help Chinese women with MBC enhance their resilience levels, biopsychosocial functions, and potentially extend their life span. Methods: A total of 226 women with MBC were randomly assigned, in a 1 : 1 ratio, to an intervention group (IG) that participated in BRBC or to a control group (CG) that received no intervention. Be Resilient to Breast Cancer was conducted for 120 min once a week. Primary outcomes were cancer-specific survival and secondary outcomes were resilience, Allostatic Load Index (ALI), anxiety, depression, and quality of life (QoL). The Cox proportional-hazards model was used for survival analysis and growth mixture models were performed for secondary outcomes. Results: Be Resilient to Breast Cancer did not significantly prolong 3-or 5-year survival (median survival, 36.7 months in IG and 31.5 months in CG). The hazard ratio for death was 0.736 (95% CI, 0.525-1.133, P = 0.076; univariate Cox model) and 0.837 (95% CI, 0.578-1.211, P = 0.345; multivariate Cox analysis). The IG improved in anxiety (ES = 0.85, P<0.001), depression (ES = 0.95, P<0.001), QoL (ES = 0.55, P<0.001), resilience (ES = 0.67, P<0.001), and ALI (ES = 0.90, P<0.001) compared to CG. Conclusions: BRBC does not improve survival of women with MBC in this study, though longer follow up is warranted. It positively impacts resilience, QoL, ALI, and emotional distress.
基金:
State Administration of Traditional Chinese Medicine [ZYZC20160901, ZYZC20160902]; Innovative Project of Guangzhou University of Chinese Medicine [2016KYTD08]; Department of Education of Guangdong Province [2012JYKY, GDHL201412015]; Guangdong Provincial Administration of Traditional Chinese Medicine [20111183]; Science and Technology Department of Guangdong Province [2011B080701081]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学
最新[2023]版:
大类|1 区医学
小类|2 区肿瘤学
第一作者:
第一作者机构:[1]Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China
共同第一作者:
通讯作者:
通讯机构:[1]Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China[2]College of Economics and Management, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China
推荐引用方式(GB/T 7714):
Ye Zeng Jie,Qiu Hong Zhong,Liang Mu Zi,et al.Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial[J].BRITISH JOURNAL OF CANCER.2017,117(10):1486-1494.doi:10.1038/bjc.2017.325.
APA:
Ye, Zeng Jie,Qiu, Hong Zhong,Liang, Mu Zi,Liu, Mei Ling,Li, Peng Fei...&Zhao, Jing Jing.(2017).Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.BRITISH JOURNAL OF CANCER,117,(10)
MLA:
Ye, Zeng Jie,et al."Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial".BRITISH JOURNAL OF CANCER 117..10(2017):1486-1494